Page 107 - Sohini Das

Telcos operating under stress as adjusted gross revenue down by 6.4%

Telcos pay SUC and licence fees to the DoT on the basis of their AGR

Finally, Indian pharmaceutical industry scores on compliance with USFDA

2018 saw remedial work finally bearing fruit

Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market

Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs

Vodafone Idea board approves Rs 25,000 crore rights issue at 60% discount

Discount of 33% to post-issue adjusted price, 60% to current price

Domestic stent market on a healthy growth track despite price controls

According to industry estimates in 2018 calendar year the overall Indian cardiac stent market grew by 16-18 per cent in terms of volumes

RCom, Reliance Jio terminate agreement for sale of telecom assets

RCom has cited delays in approval from the government and lenders as the reason

Novartis, Gilead veteran named Glenmark's innovative business CEO

Riva's appointment as CEO of Glenmark's innovation business is effective from April 2.

Price cap on cancer drugs likely to dent profit margins of hospitals

Industry insiders pointed out that almost 70% of oncology drugs are sold through the hospital channel

Sun Pharma net profit up four-fold to Rs 1,242 crore in Dec quarter

The company may also spend more on research and development (R&D) next year owing to clinical trials for new indications of its recently launched product Ilumya and others

Ashutosh Raghuvanshi appointed Fortis Healthcare CEO with effect from March

He replaces Bhavdeep Singh, who had tendered in his resignation as the CEO on November 8 last year citing professional and personal reasons

RCom goes to NCLT to speed up Jio deal, hopes move will expedite DoT nod

On Monday, RCom also moved the NCLAT to withdraw its opposition to an insolvency petition filed by Ericsson India in the NCLT

By March, a quarter of Reliance Jio subscribers to be JioPhone users

By 2021, analysts estimate over 40 per cent of Jio's subscribers would be smartphone users

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Sun Pharma in damage control mode after stock loses about 30% of its value since Sept due to corporate governance concerns

Regrow's cell therapy product gets orphan drug status from USFDA

Start-up in talks with MNCsto out-license Ossgrow for developed markets

Sun Pharma moves Sebi as stock dips on fresh whistle-blower allegations

Sun Pharma on Friday urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower

Jio PAT beats Street estimates, up 65% y-o-y on robust user addition

RIL reiterated plans to hive off the fibre and tower businesses into separate companies to manage spend on these capex heavy business segments

Biocon likely to channelise investments towards non-insulin biologics

Globally, the insulin business has come under pressure

Indian pharma industry records 9.4% growth in 2018, dispels GST gloom

The industry performed better in 2018, in comparison, on a GST-impacted low base

Reliance Jio may capture 51% revenue market share in 3 years: Analysts

Airtel and Vodafone Idea are also trying to expand the penetration of fourth-generation technology (4G) users in their subscriber base as they take this network to the hinterland

DPCO amendment may benefit MNC device makers by allowing price control

Local industry fears global firms will register equipment as 'innovative' to secure price control waiver for 5 years